NCT04569799View on ClinicalTrials.gov

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

October 11, 2022

Study Completion Date

October 11, 2022

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Lumason

2.4 mL per lesion

Trial Locations (1)

17033

Penn State Hershey Medical Center, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER

NCT04569799 - Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE | Biotech Hunter | Biotech Hunter